Dihexa

Dihexa is a modified angiotensin IV derivative engineered for blood-brain barrier penetration, with hexanoic acid and aminohexanoic acid modifications that raise lipophilicity substantially over the parent peptide. Its published profile centres on potentiation of hepatocyte growth factor signalling through the c-Met receptor, and the potency figures reported in the synaptogenesis literature are strikingly high relative to comparator neurotrophic compounds.

It is a small molecule by peptide standards — under 600 Da — and its lipophilicity creates a practical handling difference from everything else in this category: it does not dissolve well in water. DMSO stock followed by dilution into aqueous buffer is the standard approach, and the DMSO concentration in the final working solution needs to be controlled and reported, because it is not negligible in sensitive assays.